Novel therapy may prove effective in treatment of 30 percent of cancers

May 13, 2009

A ground-breaking Canada-wide clinical trial led by Dr. Katherine Borden, at the Institute for Research in Immunology and Cancer (IRIC) of the Université de Montréal, has shown that a common anti-viral drug, ribavirin, can be beneficial in the treatment of cancer patients. Published in the journal Blood (First Edition), the study demonstrates that ribavirin suppresses the activities of the eIF4E gene in patients. This gene is dysregulated in 30 percent of cancers including breast, prostate, head and neck, colon and stomach cancer.

The study, inspired by the exciting discoveries made by Dr. Borden at IRIC, was a joint project between her research group, who monitored molecular events in trial patients, and Dr. Sarit Assouline of the Segal Centre, Jewish General Hospital, who led the clinical part of the trial.

The integration of these two teams made it possible to rapidly move from a research lab to patient tests. The study team targeted the gene by giving trial participants a mimic of its natural target, ribavirin. "Our results are the first to show that targeting eIF4E in humans is clinically beneficial," explains Dr. Borden. "We also found that ribavirin not only blocks eIF4E, it has no side effect on patients."

The trial studied with M4/M5 acute myeloid leukemia who had undergone several other treatments that had previously failed. "We had striking clinical improvements with even partial and complete remissions," indicated Assouline.

Dr. Wilson Miller, director of the Clinical Research Unit, Jewish General Hospital, and co-investigator in the trial added: "It's rare that discoveries in basic research move to clinical so quickly and successfully."

The next challenge for this team is to overcome the resistance that develops over time to ribavirin. "Combination therapy with chemotherapeutic agents may enhance the efficacy of this treatment," explains Borden, "Trials in the near future are planned to overcome this and we are looking forward to more complete remissions. We also hope to test whether ribavirin is as effective in the treatment of other cancers with dysregulated eIF4E. Our laboratory studies suggest this is likely."

The study team also included Drs. Brian Leber from McMaster University/Hamilton Health Sciences (Ontario) and Denis-Claude Roy from Hôpital Maisonneuve-Rosemont in Montreal. The study was made possible thanks to a $600,000 grant awarded to Dr. Borden by The Leukemia and Lymphoma Society (USA).

More information: Sarit Assouline, Biljana Culjkovic, Eftihia Cocolakis, Caroline Rousseau, Nathalie Beslu, Abdellatif Amri, Stephen Caplan, Brian Leber, Denis-Claude Roy, Wilson H. Miller Jr, and Katherine L.B. Borden. "Molecular targeting of the oncogene eIF4E in AML: a proof-of-principle clinical trial with ribavirin" Blood First Edition Paper, prepublished online May 11, 2009; DOI 10.1182/blood-2009-02-205153

Source: University of Montreal (news : web)

Explore further: Test predicts response to treatment for complication of leukemia stem cell treatment

add to favorites email to friend print save as pdf

Related Stories

Older AML patients show promising response in drug study

Dec 08, 2008

Older patients with acute myloid leukemia (AML) who were once told that nothing could be done for them are finding new hope – and life – through a clinical trial at The Ohio State University Comprehensive Cancer Center ...

Scientists develop new drug to outflank cancer resistance

Dec 11, 2007

A new drug has shown promising results against breast and prostate cancer cells and tumours that are resistant to conventional hormone-based treatments, according to research published in the British Journal of ...

FDA OKs vitamin C trial for cancer

Jan 12, 2007

Federal approval of a clinical trial on intravenous vitamin C as a cancer treatment lends credence to alternative cancer care, U.S. researchers said.

Recommended for you

Suppressing a protein reduces cancer spread in mice

11 hours ago

Scientists have found that decreasing the levels of or blocking a specific protein commonly found in humans and many other animals allowed them to slow the spread of two different kinds of cancer to the lungs ...

User comments : 1

Adjust slider to filter visible comments by rank

Display comments: newest first

Enlightened
not rated yet May 14, 2009
This is one of many amazing stories on the breakthroughs in Cancer research, I have found here on Physorg.

My question is this - How can these incredible advances be practically applied NOW?


I have a Grandmother who suffers from Leukemia in Lake City, FL and no one in my family including her have the current scientific insight to pursue forward thinking doctors and new therapies that may save her. I have taken it upon myself to find her help, and if any of you reading this can assist me - PLEASE CONTACT ME.

Are there any other ways to acquire or request ribavirin from a doctor?

Do you know of any forward-thinking Hematologists in the state of Florida?

If anyone is familiar with the radio therapies introduced by John Kanzius and further advanced with Gold and Carbon Nanotubes/Particles, and knows of any Florida doctors that are willing to try such therapy - also PLEASE CONTACT ME.

Thank you

Drew French

(please see profile for contact info)

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.